Maria Moogerfeld, MD
Internal Medicine · Statesboro, GANPI 1750439436
Payments from drug & device makers
Across 59 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$262
- Lilly USA, LLC$92
- Novartis$64
- Abbott$60
- Xeris Pharmaceuticals, Inc.$58
- Novo Nordisk$55
- plus $420 from 19 others
What the payments were for
- Food & beverage$99799%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 16 | $262 |
| Lilly USA, LLC | 5 | $92 |
| Novartis | 3 | $64 |
| Abbott | 3 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $58 |
| Novo Nordisk | 3 | $55 |
| Pfizer | 3 | $53 |
| AstraZeneca | 3 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Boehringer Ingelheim | 2 | $27 |
| Johnson & Johnson | 2 | $26 |
| Merck | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| AbbVie | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Nevro Corp. | 1 | $19 |
| Exact Sciences | 1 | $17 |
| GSK | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$1,012 in reported general payments places this provider in the 65th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 101 | $139,131 |
| FarxigaDapagliflozin Propanediol | 43 | $54,518 |
| JanuviaSitagliptin Phosphate | 35 | $47,223 |
| JardianceEmpagliflozin | 37 | $39,710 |
| EliquisApixaban | 39 | $39,340 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $24,165 |
| Repatha SureclickEvolocumab | 37 | $22,919 |
| TradjentaLinagliptin | 26 | $18,456 |
| LinzessLinaclotide | 16 | $14,619 |
| TrulicityDulaglutide | 13 | $13,143 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $10,863 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $9,771 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,169 |
| Rosuvastatin Calcium | 365 | $7,323 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $55 | $139,131101 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Crestor | $42 | $73,44991 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $27 | $67,93776 claims |
| MerckJanuvia | $24 | $47,22335 claims |
| PfizerEliquis | $53 | $39,34039 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $16 | $37,70166 claims |
| AbbVieLinzess, Synthroid | $21 | $17,06648 claims |
| Lilly USA, LLCTrulicity | $92 | $13,14313 claims |
| Sanofi-aventis U.S. LLCLantus | $20 | $2,31719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Statesboro
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.